|Ticker||Current Price||% Daily Change||Volume (1,000s)||Average Volumn (1,000s)||Market Cap (Millions)||1/2/2020 Price||% Change Since Inception 1/2/2020|
INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to save and protect lives worldwide. The company is focused on rapidly bringing to market precisely designed and delivered DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases.
With 15 current clinical programs, INOVIO’s DNA medicines have consistently activated safe, robust, and fully functional T cell and antibody responses against targeted pathogens and cancers.
In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).